Assay development optimisation & technology

Bio-Rad’s Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel is a ready-to-use, qualitative multiplex immunoassay panel which has been designed to provide quick, precise detection of IgG antibodies against four SARS-CoV-2 antigens. This “provides useful information about natural exposure rates in a population or about vaccine immunogenicity,” said Candice Cox, Bio-Rad Immunoassays Marketing Manager, Life […]

Patricia Ahrweiler, Field Marketing Manager, Gyros Protein Technologies explains how its Gyrolab Bioaffy 4000 CD extends Gyrolab assay sensitivity to the low picogram level for improved analysis of biomarkers Biomarker research has accelerated in recent years, driving the development of novel biomarker candidates and panels for the study of a range of diseases. A case in […]

The Winter 2020/21 issue of DDW is now available in print and via the DDW App, featuring the latest innovation and insight from the drug discovery and development community. This season’s issue contains features on vaccines and immunology, AI and the US biotech sector plus expertise from companies such as PerkinElmer, Thermo Fisher Scientific and […]

Today’s episode on the topic of Innovation and Opportunity in Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Japanese drug development: Where is the innovation, Where are the opportunities in global drug discovery, and New for Old: The value behind drug repurposing. These articles were written by Lu […]

Dr J. Mark Treherne, Dr Christian Pernstich and Dr Michael Jones examine how the controlled release of proteins will  improve the reproducibility of cell-based drug discovery screens? Cell-based screening systems are now routinely incorporated as pivotal decision-making assays much earlier into the drug discovery process across most therapeutic areas and increasingly so for more complex […]

LSBio, a provider of antibodies and life science research reagents, has acquired UK-based Absolute Antibody, its sister company Kerafast. LSBio provides IHC-validated reagent antibodies and services to the global community of academic, pharmaceutical and biotech researchers. The company has built a catalogue of more than 750,000 reagent antibodies, assay kits, proteins, and biochemicals, and its […]

In this free webinar, Dr Nick Holliday, Chief Scientific Officer, Excellerate Bioscience will provide exclusive insight into the importance of kinetic assays in the drug discovery process. Viewers will gain knowledge on kinetic assay design and how to design assays that deliver hits with higher physiological relevance. Putting the dynamics into compound profiling: using kinetic […]

PerkinElmer will acquire Horizon Discovery for approximately $383 million (£296 million). The transaction is expected to close in the first quarter of 2021 subject to conditions. The investment will allow PerkinElmer to expand its portfolio of leading, automated life sciences discovery and applied genomics solutions to include gene editing and gene modulation tools. The acquisition […]

A research team at the National Center for Advancing Translational Sciences (NCATS), an arm of the National Institutes of Health (NIH), is working with PerkinElmer’s AlphaLISA immunoassay to help support the global search for effective COVID-19 therapeutics. The NCATS research project is focused on studying small molecule drug compounds that are already approved and in […]

Dr. Kacey Ronaldson-Bouchard (pictured) explains why adapting cell-based assays from suspension cells to 2D culture, 3D culture, and beyond to ‘patient in a dish’ systems is not an exercise undertaken lightly. However, the effort pays off on many levels.  Our incomplete understanding of human biology and the limited potential for human experimentation underscore the need for […]